DEERFIELD, IL–(Nov 19, 2013) – Horizon Pharma, Inc. (NASDAQ: HZNP) (“Horizon” or the “Company”) today announced that it has entered into note purchase agreements with investors to issue $150 million aggregate principal amount of 5.00% Convertible Senior Notes due 2018 (the “Notes”). The initial conversion price of the Notes will be $5.36, representing a conversion premium of approximately 20% over the last reported sale price of Horizon’s common stock on the NASDAQ Global Market on November 18, 2013. In connection with the pricing of the offering, the Company also entered into capped call transactions described below, which are generally intended to reduce the potential dilution to Horizon’s common stock upon conversion of the Notes, and thereby are expected to raise the effective conversion premium of the Notes for Horizon to approximately 50% over the last reported sale price of Horizon’s common stock on the NASDAQ Global Market on November 18, 2013.

The purchase of the Notes is expected to close on November 22, 2013, subject to the satisfaction of customary closing conditions. The Notes will be issued at a price equal to 100% of the principal amount thereof. The net proceeds from the sale of the Notes, after deducting fees and expenses, are expected to be approximately $143.8 million. Of the net proceeds from the offering, Horizon anticipates using $18.7 million to pay the cost of the capped call transactions, $35.0 million to fund the Horizon’s proposed acquisition of VIMOVO^®, $70.4 million to repay all obligations under the Company’s existing senior secured loan, including required make-whole payments, and the remainder of approximately $19.7 million for working capital and general corporate purposes.

The Notes will bear interest at a fixed rate of 5.00% per annum, payable semiannually in arrears on May 15 and November 15 of each year, beginning on May 15, 2014, and will mature on November 15, 2018, unless earlier repurchased or converted.

The Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding August 15, 2018 only under certain conditions. On or after August 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date for the Notes, holders will be able to convert their Notes at their option at the conversion rate then in effect at any time, regardless of these conditions. Subject to certain limitations, Horizon may settle conversions of the Notes by paying or delivering, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. If Horizon undergoes a fundamental change prior to the maturity date for the Notes, the holders may require the Company to repurchase for cash all or any portion of their notes at a price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest.

The initial conversion rate will be 186.4280 shares of common stock for each $1,000 principal amount of Notes, which represents an initial conversion price of approximately $5.36 per share of common stock. The capped call transactions described below will increase the effective conversion price of the Notes for Horizon to approximately $6.71 per share. The conversion rate of the Notes, and the corresponding conversion price, will be subject to adjustment for certain events, but will not be adjusted for accrued and unpaid interest.

Horizon may not redeem the Notes prior to their maturity date, and there is no sinking fund provided for the Notes.

In connection with the pricing of the Notes, Horizon entered into privately negotiated capped call transactions with certain financial institutions (the “hedge counterparties”). The capped call transactions are generally expected to reduce potential dilution to Horizon’s common stock upon conversion of the Notes in excess of the principal amount of such converted Notes. The cap price of the capped call transactions will initially be approximately $6.71, which represents a premium of approximately 50% over the last reported sale price of the Company’s common stock on the NASDAQ Global Market on November 18, 2013 and is subject to certain adjustments under the terms of such capped call transactions.

Horizon has been advised by the hedge counterparties that in connection with establishing their initial hedges of the capped call transactions, the hedge counterparties (or their affiliates) expect to enter into various derivative transactions with respect to Horizon’s common stock concurrently with, and/or purchase shares of Horizon’s common stock shortly after, the pricing of the Notes. These activities could have the effect of increasing, or reducing the size of any decrease in, the price of the Notes and/or Horizon’s common stock.

The offering of the Notes was limited to accredited investors and qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder. Neither the Notes nor any shares of Horizon’s common stock issuable upon conversion of the Notes have been or are expected to be registered under the Securities Act or under any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Horizon Pharma

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS^® and RAYOS^®/LODOTRA^® and will market VIMOVO^®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit www.horizonpharma.com.

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the expected acquisition of the U.S. rights to VIMOVO, the expected closing of Horizon’s offering of the Notes and Horizon’s receipt and use of the net proceeds therefrom, the terms of the Notes and the anticipated impacts of the capped call transactions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to risks regarding the closing of the acquisition and the offering of the Notes, Horizon’s ability to satisfy the closing conditions for the offering of the Notes, and Horizon’s ability to complete the offering of the Notes on the anticipated terms, or at all. For a further description of these and other risks facing the Company, please see the risk factors described in the Company’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in those filings. Forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts
Investors
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Email Contact

Media
Justin Jackson
Burns McClellan, Inc.
212-213-0006
Email Contact

SAN DIEGO, Nov. 19, 2013 — Cardium Therapeutics (NYSE MKT: CXM) today presented its financial results for the third quarter ended September 30, 2013, and reported on recent highlights and other business developments including:

• Sale of To Go Brands® business to Cell-nique Corporation and Healthy Brands Collective® in an asset purchase for approximately $2.5 million through the exchange of a preferred equity position in Healthy Brands. Healthy Brands is a private operating company that has acquired eight brand platforms in the health and nutraceutical space and has previously reported plans to move forward as a public company as its businesses advance through internal growth and by further acquisition.
• Market introduction of LifeAgain’s BlueMetric Select term life insurance program for men with active localized prostate cancer issued by Symetra Life Insurance Company. The BlueMetric Select program is based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™), which was internally developed by researchers at Cardium.
• Publication of “Serial Sharp Debridement and Formulated Collagen Gel to Treat Pressure Ulcers in Elderly Long-term Care Patients: A Case Study”, in the November 2013 issue of Ostomy Wound Management, highlighting Excellagen’s capability of promoting rapid granulation and healing in chronic pressure ulcers in elderly long-term care facility residents.
• Distribution agreements with (1) AvKARE Inc. for the sale and distribution of Excellagen into government medical facilities throughout the United States. AvKARE services a diverse customer base that includes government (federal, state and municipal) and commercial sectors, and (2) international distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen in Germany and Switzerland.
• New FDA 510(k) submission for Cardium’s current FDA-cleared Excellagen to reflect additional and specific structural and functional properties based on the Company’s supplemental research and development activities.
• Research collaborations with (1) Orbsen Therapeutics Ltd and the National University of Ireland, Galway, to utilize Excellagen in pre-clinical studies as a delivery agent for Orbsen’s proprietary stromal cell therapy for the potential treatment of diabetic foot ulcers, and (2) researchers at Boston Children’s Hospital, to assess the medical utility of Excellagen as a scaffold to seed autologous mesenchymal fetal stem cells for ex-vivo engineering of tissue grafts for transplantation into infants to potentially repair prenatally diagnosed birth defects.
• Completion of a 1:20 reverse stock split of the Company’s common stock and closing of the second tranche of the securities purchase agreement with one of its institutional investors consisting of 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, both of which were approved at the 2013 annual meeting of stockholders.
• Instituted a series of cost reduction actions that include relocation of the corporate offices to a smaller and lower cost facility, reduced employee headcount and across the board salary reductions. The impact of these measures will be reflected in the fourth quarter.

Report on LifeAgain Advanced Medical Analytics

During the third quarter, LifeAgain Insurance Solutions, Inc., Cardium’s newly-formed advanced medical data analytics business focused on the development, marketing and sale of “survivable risk” term life insurance programs, and AgencyONE, its commercialization partner, entered into agreements to market and sell term life insurance issued by Symetra Life Insurance Company under LifeAgain’s BlueMetric Select term life insurance program for men with active localized prostate cancer.  The BlueMetric Select program was developed based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™) and was specifically designed to provide eligible men with term life insurance coverage following a prostate cancer diagnosis or upon the completion of a prostate cancer surgery, without the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies.

The BlueMetric Select program has been designed for men aged 45-65, who are in otherwise good health and who have low- to medium-risk active localized prostate cancer, which has been confirmed by a recent biopsy, and for men who have recently completed prostate cancer surgery. This program seeks to provide term life insurance coverage and may include an automatic renewal option (following the initial ten-year term), the right to convert into universal life insurance, and an accelerated benefit in the event of a terminal illness. The BlueMetric Select Program is designed to offer substantial coverage levels, ranging from $100,000 to $1,000,000, without waiting periods, so an individual can begin the application process on the day of his prostate cancer diagnosis, or immediately following completion of prostate cancer surgery.  Additional information is at www.lifeagain.com.

LifeAgain’s proprietary Advanced Medical Data Analytics Platform Technology enables a scalable, actuarial-based risk assessment based on a diagnostic histological biopsy or a prostate cancer surgery.  Together with an applicant’s overall health, these factors may be used to support favorable underwriting decisions and to establish appropriate premium pricing based on the level of prostate cancer progression of each applicant.  LifeAgain is developing additional new and innovative insurance solutions for other medical conditions currently considered uninsurable by traditional underwriters.

Excellagen Update

Cardium recently announced the publication of “Serial Sharp Debridement and Formulated Collagen Gel to Treat Pressure Ulcers in Elderly Long-term Care Patients: A Case Study”, in the November 2013 issue of Ostomy Wound Management, highlighting Excellagen’s capability of promoting rapid granulation and healing in chronic pressure ulcers in elderly long-term care facility residents.  The paper can be accessed at http://www.o-wm.com/article/serial-sharp-debridement-and-formulated-collagen-gel-treat-pressure-ulcers-elderly-long-term.

In third quarter 2013, Cardium filed a 510(k) submission for its current FDA-cleared Excellagen advanced wound care product to reflect additional and specific structural and functional properties based on the Company’s supplemental research and development activities.  The new 510(k) submission is designed to provide further mechanistic insight into the significantly accelerated and activated healing response seen with Excellagen.  In addition, the Company plans to modify Excellagen’s packaging to include individually pouched applicator syringes and a large volume syringe applicator to allow for easier use in larger-sized wounds such as those found in limb salvage, orthopedic surgery and other surgical applications.

The Company entered into a distribution agreement with AvKARE Inc., its new sales and distribution partner for Excellagen in Veterans Hospitals and other governmental medical facilities throughout the United States. The new agreement and commercialization arrangement with AvKARE effectively replaces an earlier arrangement with Academy Medical, LLC.  Cardium elected to transfer the Excellagen distribution responsibilities to AvKARE, which provides five direct wound care experts and allows Cardium’s distributor representatives access to all government accounts.  AvKARE services a diverse customer base that includes government (federal, state and municipal) and commercial sectors.

In addition, during third quarter Cardium entered into a distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen in Germany and Switzerland, with the potential for expansion into additional European markets.  Kasiak Holdings is focused on developing stem cell-based therapeutics for the treatment of diabetic foot ulcers.  Kasiak Holdings is affiliated with Kasiak Research, which is an operating unit of India-based Bharat Serums and Vaccines, that develops and manufactures specialized biological, pharmaceutical and biotechnology products.

The Company also announced research collaborations with (1) Orbsen Therapeutics Ltd and the National University of Ireland, Galway, to utilize Excellagen in pre-clinical studies as a delivery agent for Orbsen’s proprietary stromal cell therapy for the potential treatment of diabetic foot ulcers, and (2) researchers at Boston Children’s Hospital, to assess the medical utility of Excellagen as a scaffold to seed autologous mesenchymal fetal stem cells for ex-vivo engineering of tissue grafts for transplantation into infants to potentially repair prenatally diagnosed birth defects.

Regarding Excellagen’s CE mark submission, Cardium has reported that based on the current status, all information requests have been provided to the notified body, BSI and that the Company believes this process should lead to CE mark certification for its FDA-cleared advanced wound care product.

Report on To Go Brands and Health Sciences Businesses

On November 18, 2013, the Company announced that Cell-nique Corporation, which owns a variety of innovative businesses that are part of the Healthy Brands Collective®, has acquired To Go Brands® in an asset purchase for approximately $2.5 million through an exchange of a preferred equity position in Healthy Brands.

Consistent with Cardium’s business model of developing businesses that can be partnered or monetized with larger enterprises, Healthy Brands has been making significant acquisitions and has previously reported plans to move forward as a public company as its businesses advance through internal growth and by further acquisition.

Through recent acquisitions and the purchase of Cardium’s To Go Brands business,  Healthy Brands’ portfolio now includes nine independent brand product platforms including Cell-nique®, Cherrybrook Kitchen®, Yumnuts®, Living Harvest/Tempt®, Bites of Bliss®, Funky Monkey®, High Country Kombucha® drinks and Organics European Gourmet Bakery™ (Dr. Oetker) natural and organic baking mixes.

Cell-nique is not yet a public reporting company, but annualized revenue is currently estimated to exceed $13.0 million, without giving effect to its recently-completed acquisitions of the Funky Monkey and To Go Brands businesses. Cardium’s preferred stock position in Cell-nique is convertible into common stock currently representing approximately 4% of the fully-diluted common stock, it accrues an 8% annual dividend, and it comes with certain rights and preferences described in Cell-nique’s articles of incorporation. For more information on Cell-nique and the Healthy Brands Collective, visit www.healthybrandsco.com.

Cardium, through its health sciences unit, will retain the trademarks and technology relating to the MedPodium® Nutra-apps® and nutraceutical product line, and will retain its investment interest in SourceOne, a nutraceutical and health sciences ingredient supplier.

The sale of the To Go Brands unit is Cardium’s second development and monetization of a portfolio business. Its InnerCool subsidiary was advanced and sold to a U.S. affiliate of Philips for approximately $12.5 million.

Financial Report

Product sales for the three months ended September 30, 2013 totaled $472,000, compared to $5,600 for the same period in 2012.  Product sales for the nine months ended September 30, 2013 were $1.7 million, compared to $39,000 for the nine months ended September 30, 2012.  The increase in product sales was comprised of sales from the Company’s To Go Brands health sciences business, which Cardium acquired in late September 2012.

Cardium’s research and development costs for the third quarter ended September 30, 2013 totaled $0.3 million, and selling, general and administrative expenses were $1.6 million, compared to $0.5 million and $1.4 million, respectively, for third quarter ended September 30, 2012.  For the nine months ended September 30, 2013, research and development costs were $1.6 million, and selling, general and administrative expenses were $5.3 million, compared to $2.1 million and $4.4 million, respectively, for the nine months ended September 30, 2012.  Research and development expenses for the nine months ended September 30, 2013 included milestone payments and out-of-pocket costs for the ASPIRE study and product and testing costs for validating production volume and cost efficiency improvements for Excellagen.

For the three months ended September 30, 2013, the Company reported a net loss of $1.9 million, or $(0.28) per share, when compared to a net loss of $1.9 million, or $(0.32) per share for the three months ended September 30, 2012.  For the nine months ended September 30, 2013, the Company reported a net loss of $6.6 million, or $(0.99) per share, compared to a net loss for the nine months ended September 30, 2012 of $6.4 million, or $(1.10) per share.  As of September 30, 2013, the Company had $585,000 in cash and cash equivalents, compared to $2.3 million in cash and cash equivalents on December 31, 2012.  On September 30, 2013, 7,747,228 million shares of Cardium’s common stock were outstanding.

The sale of To Go Brands is intended to monetize that business by positioning it with a diversified, fast growing platform.  Cardium’s preferred stock position in Cell-nique is convertible into common stock currently representing approximately 4% of the fully-diluted common stock, it accrues an 8% annual dividend, and it comes with certain rights and preferences described in Cell-nique’s articles of incorporation. Cardium could also elect to sell or otherwise monetize its preferred stock position in Cell-nique in one or more transactions.

The To Go Brands transaction also included the transfer of certain operating expenses and liabilities to Healthy Brands Collective, which will further reduce the Company’s operating expenses. In addition, during third quarter, Cardium implemented certain cost reductions that include relocating the Company to a smaller corporate office, as well as headcount and salary reductions.

The Company intends to consider additional corporate development transactions designed to place its product candidates or businesses into larger organizations or with partners having existing commercialization, sales and marketing resources, and a need for innovative products. Such transactions could involve the sale, partnering or other monetization of particular product opportunities or businesses. In parallel, as the Company’s businesses are advanced and corresponding valuations established, it plans to pursue new product opportunities and acquisitions with strong value enhancement potential.

Cardium has also been approached by a strategic investor interested in potentially acquiring a stake in the company at a premium to market, although we have not entered into definitive agreements for such a transaction.

Depending on the extent and timing of such product advancements, business monetizations and strategic or other investments, and based on recently-issued amendments to Rule 506 and Rule 144A under the Securities Act of 1933 that were implemented under Section 201(a) of the Jumpstart Our Business Startups Act (the “JOBS Act”), we may also consider financings through the sale of private equity interests to qualified investors or strategic partners based on the JOBS Act amendments, and/or through other private placements or a public offering of securities, which could potentially be made in the parent company or independently in one or more of our subsidiary business units.

In third quarter 2013, Cardium completed a 1:20 reverse split of the Company’s common stock and announced the completion of the second tranche of a registered direct offering with one of its institutional investors consisting of 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million.  During third quarter 2013 and as of the date of this report, the Company has not sold any common stock under its “at-the-market” facility.

As previously reported, a communication from the staff of the Company’s current listing exchange, NYSE MKT, indicated that the Company was considered to be noncompliant with certain listing requirements based on its quarterly report for the period ended September 30, 2012, and provided that the company should submit a plan to staff of the exchange that would reestablish compliance with the NYSE MKT listing requirement by March 31, 2013.  On December 6, 2012, the company reported that it had submitted a plan designed to reestablish compliance with the exchange’s requirement in advance of the March 31, 2013 time frame, and on January 6, 2013, announced that the plan had been accepted by the listing exchange.  On April 5, 2013, the Company reported that the NYSE MKT had granted an additional quarterly extension of the listing exchange compliance plan from March 31 to June 30, 2013.  On July 2, 2013, the Company reported that its exchange had granted an additional quarterly extension of the listing exchange compliance plan from June 30, 2013 to September 30, 2013.  On October 7, 2013, the Company reported that the NYSE MKT had granted an additional quarterly extension of the listing exchange compliance plan from September 30, 2013 to December 31, 2013.  If Cardium does not achieve and maintain compliance in accordance with its plans, it could be subjected to delisting proceedings. However, as part of the Company’s overall cost reduction efforts, Cardium has also considered relisting its common stock on the OTC Market, on which its stock regularly traded prior to its listing on the American Stock Exchange.

About Excellagen

Excellagen is a sterile, syringe-based, professional-use, physiologically formulated homogenate of purified bovine dermal collagen (Type I) in its native, 3-dimensional fibrillar configuration, providing a structural scaffold for cellular infiltration and wound granulation. Excellagen activates platelets, triggering release of essential growth factors and functions as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue.    Excellagen’s FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen’s unique fibrillar Type I bovine collagen homogenate formulation is topically applied through easy-to-control, pre-filled, sterile, single-use syringes and is designed for application at only one-week intervals.  For more information about Excellagen, visit www.excellagen.com.

About Generx

Generx [Ad5FGF-4] alferminogene tadenovec is a disease-modifying regenerative medicine biologic that is being developed to offer a one-time, non-surgical therapy for the treatment of cardiac microvascular insufficiency due to myocardial ischemia in patients with stable angina due to advancing coronary artery disease.  Similar to surgical and mechanical revascularization approaches, the goal of Cardium’s Generx product candidate is to improve blood flow to the heart muscle, following a single, non-surgical administration using a standard balloon angioplasty catheter.  The ASPIRE Phase 3 registration study is currently being conducted at leading cardiology centers in the Russian Federation to evaluate the continued safety and therapeutic effects of Generx.  For more information about Generx and the ASPIRE clinical study, visit www.cardiumthx.com/generx.html.

About LifeAgain

LifeAgain Insurance Solutions is an advanced medical data analytics business and life insurance agency that is focused on the development, marketing and sale of “survivable risk” term life insurance programs for cancer survivors or others with medical conditions who are currently considered uninsurable based on traditional underwriting standards.  Working in cooperation with large and established life insurance companies, LifeAgain uses new actuarial methods, and scientific and medical data-driven insights to design life insurance solutions for those who may otherwise not be able to obtain coverage.  LifeAgain’s initial focus is on the development, marketing and sale of survivable risk life insurance for men with active localized prostate cancer.  LifeAgain plans to develop additional new and innovative life insurance solutions for men and women with other medical conditions. For more information about LifeAgain, visit www.lifeagain.com.

About Cardium

Cardium is a health sciences and biotechnology regenerative medicine company. Cardium has three business units: (1) Angionetic Therapeutics™, focused on the late-stage clinical development of Generx^® , an angiogenic gene therapy product candidate for the treatment for cardiac microvascular insufficiency due to advancing coronary artery disease; (2) Activation Therapeutics™, a regenerative medicine wound healing technology and commercialization platform, that includes Excellagen^®, an FDA-cleared advanced wound care product and (3) LifeAgain® Insurance Solutions, an advanced medical data analytics platform that supports the Company’s BlueMetric Select term life insurance program, which is underwritten by Symetra Life Insurance for men with active localized prostate cancer.  For more information about Cardium visit www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that Cell-nique and Healthy Brands will be successful in their business development efforts, that their company will go public, or that Cardium’s preferred stock position will result in an increase in value that can be realized by Cardium; that Cardium will be successful in advancing, capitalizing and partnering or monetizing its other businesses and technology platforms; that the Company can raise capital through the private or public sale of equity interests on a company-by-company basis or otherwise; that planned product development efforts and clinical studies can be performed in an efficient and effective manner; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the Company or its partners will be successful in developing and marketing survivable risk life insurance programs or that any intellectual property developed in the area will be effective for excluding potential competitors; that the Company will satisfy the requirements of its exchange listing compliance plan and will otherwise continue to satisfy the listing requirements of its exchange or that its shares can continue to be listed on a national exchange; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; that the Company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that our or our licensor’s intellectual property can be successfully developed and enforced and that we will not be accused of infringing on intellectual property developed by third parties; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; or that the Company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®, Excellagen^®, LifeAgain^®, BlueMetric™, Decision Rule Adaption™, ADAPT™, Angionetic Therapeutics™, Activation Therapeutics™, MedPodium^® and Nutra-Apps^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.  Other trademarks belong to their respective owners.

-Continued-

SOURCE Cardium Therapeutics

SEATTLE, WA–(Nov 18, 2013) – Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced that on November 14, 2013, Atossa attended a pre-510(k) submission meeting with the Food and Drug Administration and discussed the regulatory pathway and data requirements to support Atossa’s planned 510(k) Premarket Notification submission for the ForeCYTE Breast Pump and patient kit. Atossa reports that the meeting was productive and will help inform the strategy, content, and timing of the regulatory requirements for the medical device.

Based partially on feedback from the meeting, Atossa plans to submit a 510(k) notification to the FDA related to the ForeCYTE Breast Pump and patient kit. Atossa believes that it has the data and other information to support this submission and intends to file the 510(k) with the FDA as soon as possible. Atossa intends to continue working with the FDA as the 510(k) is prepared, submitted, and reviewed by the FDA for its specific claims.

About Atossa Genetics

Atossa Genetics, Inc. is focused on proprietary products and services related to breast health through the commercialization of medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc., the offering of laboratory services and tests. For additional information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the feedback from the pre-submission meeting and actions related thereto, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa’s ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa’s products and services, the market demand for and acceptance of Atossa’s products and services, performance of distributors, estimated future expenses and cash needs, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact:

Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Email Contact

MBS Value Partners
Matthew D. Haines (Investors and Media)
Managing Director
(O) 212-710-9686
Email Contact

MANCHESTER, NH–(Nov 18, 2013) – Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), an innovative developer of drugs that address diabetes using complex carbohydrate chemistry, will be presenting at the Elsevier Therapeutic Area Partnerships (“TAP”) 2013 Conference at The Hyatt Regency in Boston on Tuesday, November 19 from 2:15 pm to 3:05 pm ET within Track 4 (Cardiovascular/Metabolic Diseases).

Kenneth A. Tassey, Jr., President of Boston Therapeutics, will present information about PAZ320, an investigational non-systemic chewable tablet that when taken as an adjunctive therapy helped 45% of the patients with Type II diabetes manage the post-meal elevation of their blood sugar in a Phase IIa clinical trial.

For the conference, Boston Therapeutics was chosen as one of 10 “Top Projects to Watch” within the area of cardiovascular/metabolic diseases. These are handpicked by a panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The criteria were: large market, large unmet need, with increasing opportunity; history of the molecule and drug; strong science; strong company; diversity of indications; potential for new opportunities beyond the initial indications; and multilevel partnering opportunities.

Mr. Tassey said, “TAP 2013 promises to be one of the key meetings of the year within the cardiovascular/metabolic disease area. We are pleased with this opportunity to educate attendees about the potential benefits of PAZ320, and are honored to be named a ‘Top Project to Watch’ by the independent panel.”

About the Therapeutic Area Partnerships Conference

Since its launch eight years ago, Therapeutic Area Partnerships (TAP) has come to be regarded as the industry’s premier biopharmaceutical partnering event and a meeting for the sharpest minds in biopharma. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in oncology, cardiovascular/metabolic diseases, neuroscience, infectious diseases, anti-inflammatory/autoimmune diseases and advanced therapies. Attendees have the opportunity to hear from and meet some of the industry’s most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry’s most productive events. More information is available at www.elsevierbi.com/mkt/Conf/TAP2013/TAP2013.

About PAZ320

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company’s product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Vice President of Strategic Planning
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

MELBOURNE, AUSTRALIA–(Nov 15, 2013) – Prana Biotechnology (NASDAQ: PRAN) (ASX: PBT) has become aware of a news story which indirectly reference the company’s Phase II clinical drug trial of PBT2 for Alzheimer’s disease, IMAGINE.

It appears one of the patients participating in IMAGINE has suggested certain symptoms associated with Alzheimer’s disease have improved during the trial. Whilst the company was not named, images of Prana’s drug under development for Alzheimer’s disease PBT2 were used.

Prana was not aware of the segment and did not participate in the segment. The IMAGINE trial is a randomised, double-blind trial. Prana, the clinical investigators and the patients involved are unaware of the treatment assignment (PBT2 or a placebo).

The clinical benefit, if any, of PBT2 compared to a placebo will not be known until treatment assignment is un-blinded and the trial data analysed.

Prana expects to release the results of IMAGINE in March 2014.

Prana has made this release under ASX Guidance Note 8 Continuous Disclosure to avoid any uncertainty and has not received a request from the ASX.

About Prana Biotechnology Limited

Prana Biotechnology was established to commercialise research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s technology.

For further information please visit the Company’s web site at www.pranabio.com.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Contacts:

USA:
Vivian Chen
Grayling
T: +1 646-284-9472
Vivian.Chen@grayling.com

Australia:
Investor Relations
Rebecca Wilson
T: +61 3 8866 1216
E: rwilson@buchanwe.com.au

Media Relations
Ben Oliver
T: +61 3 8866 1233
E: boliver@buchanwe.com.au

CHARLOTTE, NC–(November 15, 2013) – Chanticleer Holdings, Inc. (NASDAQ: HOTR) (“Chanticleer” or “the Company”), a franchisee of international Hooters^® restaurants and a minority owner in the privately held parent company of the Hooters^® brand, Hooters of America (“HOA”), and owner of American Roadside Burgers Inc (“ARB”), a Charlotte, N.C. based chain, announced its financial results for the three and nine months ended September 30, 2013.

Highlights Include:

• On September 30, 2013, the Company completed our acquisition of 100% of American Roadside Burgers, Inc. (“ARB”). The Company issued 740,000 shares of its common stock and warrants to acquire 740,000 shares of common stock for $5.00 per share. In connection with the acquisition of ARB and the related management team, the Company acquired a strategic opportunity to participate in a high-growth space with an already established brand. The Company’s plan is to continue to expand the American Roadside chain as opportunities occur, which has the potential to bring additional revenue and profits to the Company in the future. The acquisition provides the Company with advisory services from one of the nation’s leading restaurant executives, Tom Lewison. The Company also hired Rich Adams, a 35 year food service veteran, as Chief Operating Officer.
• Restaurant revenue for the third quarter 2013 decreased 7.6% to $1.6 million, compared with $1.7 million in the third quarter 2012. This decrease is primarily from a decrease in the South African (“SA”) currency exchange rate to the U.S. dollar (“USD”); revenues measured in local currency increased 3.6%. Restaurant revenue for the nine months ended September 30, 2013 increased 1.5% to $4.9 million, compared with $4.8 million in the third quarter 2012. This increase occurred from having five Hooters locations operating for the full nine months of 2013, offset by the aforementioned exchange rate decline.
• As of September 30, 2013, the Company had eleven restaurants (10 consolidated and one joint venture) compared with six restaurants (five consolidated and one joint venture) as of September 30, 2012.
• Restaurant gross profit margins for the third quarter 2013 improved 5.3% to 63.5% compared with 58.2% in the same period a year ago. Restaurant gross profit margins for the nine months ended September 30, 2013 improved 4.0% to 62.2% compared with 58.2% in the third quarter 2012.
• Same-store net sales for restaurants opened more than a year increased 3.6% and 5.3% in South Africa currency (Rands) for the three and nine months ended September 30, 2013, respectively compared with last year.
• Restaurant EBITDA for the three months ended September 30, 2013 and 2012 was approximately $83,000 and $54,000, respectively, an increase of 53.7%. Restaurant EBITDA for the nine months ended September 30, 2013 and 2012 was $195,000 and $153,000, respectively, an increase of 27.5%. Our improved gross margins were offset by an increase in operating expenses, including professional fees and higher payroll costs.
• Net loss attributable to Chanticleer Holdings, Inc. from continuing operations for the third quarter 2013 was $1.4 million or $0.38 per share, compared with $721,000 or $0.19 per share for the year-ago third quarter. Total net loss for the 2013 third quarter was $1.4 million or $0.38 per share, compared with $740,000 or $0.20 per share. The increase was primarily attributable to an increase in general and administrative expenses (“G&A”) and interest expense.
• Net loss attributable to Chanticleer Holdings, Inc. from continuing operations for the nine months ended September 30, 2013 was $2.8 million or $0.77 per share, compared with $2.2 million or $1.00 per share for the year-ago period. Total net loss for the nine months ended September 30, 2013 was $2.9 million or $0.77 per share, compared with $2.3 million or $1.06 per share. The increase was primarily attributable to an increase in G&A and interest expense.

Subsequent to September 30, 2013, the Company had significant announcements:

• The Company assumed operating control of ARB on October 1, 2013. ARB is a five store burger chain currently operating 1 location in Smithtown, NY, 2 in Charlotte, NC, 1 in Columbia, SC and 1 in Greenville, SC.
• On October 17, 2013, the Company raised $2,500,000 in a private placement, pursuant to which the Company sold an aggregate of 666,667 Units (the “Units”) at a purchase price of $3.75 per Unit (“Unit Price”). Each Unit consists of (a) one (1) share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (b) one (1) five (5) year warrant, exercisable after twelve (12) months, to purchase one (1) share of common stock at an initial exercise price of five dollars ($5.00) (the “Warrants”).
• On November 6, 2013, the Company finalized the acquisition of the Hooters Nottingham restaurant for it’s previously announced purchase price of $3,150,000. On November 7, 2013, the Company took operating control of Hooters Nottingham .The restaurant will continue under it’s current management team who have over 20 years combined experience at this restaurant.
• On November 4, 2013, the Company entered into a Subscription Agreement with JF Restaurants, LLC (“JFR”), JF Franchising Systems, LLC (“JFFS”) (collectively “Just Fresh”), and the Preferred Members (the “Members” or collectively, the “Sellers”) for the purchase of a fifty one percent (51%) ownership interest in each entity. The total purchase price was $560,000 and the final closing is contingent upon the Members’ conversion of all outstanding Member notes and loans into ownership interest, to be held no later than November 20, 2013. Just Fresh currently operates five restaurants in the Charlotte, North Carolina area that offer fresh-squeezed juices, gourmet coffee, fresh-baked goods and premium-quality, made-to-order sandwiches, salads and soups.
• On November 7, 2013, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with three accredited investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 160,000 Units (the “Units”) at a purchase price of $5.00 per Unit (“Unit Price”), closing a $800,000 private placement (the “Private Placement”). The aggregate purchase price we received from the sale of the Units was $800,000. Each Unit consists of (a) one (1) share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (b) one (1) five (5) year warrant to purchase one (1) share of common stock. One half (80,000) of the available warrants are available at an initial exercise price of five dollars and fifty cents ($5.50), while the remaining half (80,000) of the warrants are available at an initial exercise price of seven dollars ($7.00) (the “Warrants”).

Mike Pruitt, Chairman and CEO of Chanticleer, commented: “We are excited to add American Roadside Burgers and Hooters Nottingham to our portfolio of restaurant companies heading into the fourth quarter of 2013. Revenue growth, gross margin improvement and growth in restaurant EBITDA give us good momentum as we enter the fourth quarter. In November we closed our purchase of the existing Hooters restaurant in Nottingham, England, which has been profitable for some time. The purchase price was $3,150,000 and the current management team will remain to operate the restaurant. Going forward, we will continue to evaluate restaurant and other opportunities at home and abroad, as well as continue to focus on performance improvement in our existing operations.”

Use of Non-GAAP Measures

Chanticleer Holdings, Inc. prepares its condensed consolidated financial statements in accordance with United States generally accepted accounting principles (“GAAP”). In addition to disclosing financial results prepared in accordance with GAAP, the company discloses information regarding EBITDA, which differs from the term EBITDA as it is commonly used. In addition to adjusting net income (loss) from continuing operations to exclude taxes, interest, and depreciation and amortization, EBITDA also excludes pre-opening costs for our restaurants, non-cash expenses for services, change in fair value of derivative liability and gain on extinguishment of debt. EBITDA is not a measure of performance defined in accordance with GAAP. However, EBITDA is used internally in planning and evaluating the company’s operating performance. Accordingly, management believes that disclosure of this metric offers investors, bankers and other stakeholders an additional view of the company’s operations that, when coupled with the GAAP results, provides a more complete understanding of the company’s financial results.

EBITDA should not be considered as an alternative to net loss or to net cash used in operating activities as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the company’s performance. A reconciliation of GAAP net income (loss) to EBITDA is included in the accompanying financial schedules.

About Chanticleer Holdings, Inc.

Chanticleer Holdings (NASDAQ: HOTR) is focused on expanding the Hooters® casual dining restaurant brand in international emerging markets and American Roadside Burgers Inc (“ARB”), a Charlotte, N.C. based chain. Chanticleer currently owns in whole or part of the exclusive franchise rights to develop and operate Hooters restaurants in South Africa, Hungary and parts of Brazil, and has joint ventured with the current Hooters franchisee in Australia, while evaluating several additional international opportunities. The Company currently owns and operates in whole or part of seven Hooters restaurants in its international franchise territories: Durban, Johannesburg, Cape Town and Emperor’s Palace in South Africa; Campbelltown in Australia; Budapest in Hungary; and Nottingham in the United Kingdom. ARB, purchased by Chanticleer Holdings on October 1, 2013, has a total of 5 casual restaurants — 1 location in Smithtown, N.Y., 2 locations in Charlotte, N.C., 1 location in Columbia, S.C., and the newest location is in Greenville, S.C

For further information, please visit www.chanticleerholdings.com
Facebook: www.Facebook.com/ChanticleerHOTR
Twitter: http://Twitter.com/ChanticleerHOTR

For further information on Hooters of America, visit www.Hooters.com
Facebook: www.Facebook.com/Hooters
Twitter: http://Twitter.com/Hooters

Safe Harbor/Risk Factors
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations, forecasts, and assumptions by our management and involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those stated, including, without limitation:

• Operating losses continuing for the foreseeable future; we may never be profitable;
• Our business strategy includes operating a new line of business that is distinct and separate from our primary existing operations, which could be subject to additional business and operating risks;
• Inherent risks in expansion of operations, including our ability to acquire additional territories, generate profits from new restaurants, find suitable sites and develop and construct locations in a timely and cost-effective way;
• General risk factors affecting the restaurant industry, including current economic climate, costs of labor and food prices;
• Intensive competition in our industry and competition with national, regional chains and independent restaurant operators;
• Our rights to operate and franchise Hooters-branded restaurants are dependent on the Hooters’ franchise agreements;
• Our business depends on our relationship with Hooters;
• We do not have full operational control over the businesses of our franchise partners;
• Failure by Hooters to protect its intellectual property rights, including its brand image;
• Our business has been adversely affected by declines in discretionary spending and may be affected by changes in consumer preferences;
• Increases in costs, including food, labor and energy prices;
• Our business and the growth of our Company is dependent on the skills and expertise of management and key personnel;
• Constraints could effect our ability to maintain competitive cost structure, including, but not limited to labor constraints;
• Work stoppages at our restaurants or supplier facilities or other interruptions of production;
• Our food service business and the restaurant industry are subject to extensive government regulation;
• We may be subject to significant foreign currency exchange controls in certain countries in which we operate;
• Inherent risk in foreign operation;
• We may not attain our target development goals and aggressive development could cannibalize existing sales;
• Current conditions in the global financial markets and the distressed economy;
• A decline in market share or failure to achieve growth;
• Unusual or significant litigation, governmental investigations or adverse publicity, or otherwise;
• Adverse effects on our operations resulting from the current class action litigation in which the Company is one of several defendants;
• Adverse effects on our results from a decrease in or cessation or clawback of government incentives related to investments;
• Adverse effects on our operations resulting from certain geo-political or other events.

Chanticleer cannot be certain that any expectation, forecast, or assumption made in preparing any forward-looking statements will prove accurate, or that any projection will be realized. It is to be expected that there may be differences between projected and actual results. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its Web site or otherwise. We undertake no obligation to update the forward-looking statements provided to reflect events or circumstances that occur after the date on which they were made. Further information on our business, including important factors which could affect actual results are discussed in the Company’s filings with the SEC, including its Annual Report on Form 10-K under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Contact:

Chanticleer Holdings, Inc.
Mike Pruitt
Chairman/CEO
Phone: 704.366.5122 x 1
mp@chanticleerholdings.com

Eric Lederer
CFO
Phone: 704.366.5736
elederer@chanticleerholdings.com

FRISCO, TX–(November 14, 2013) – OxySure®Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), today reported financial and operating results for the third quarter ended September 30, 2013.

Third Quarter 2013 Highlights :

• Total revenue increased by approximately 428% to $545,820

• Interest expense down by approximately 15% to $47,180

• Working capital deficit improved by approximately $2,204,966

• Stockholder deficit improved by approximately $2,080,000

• Gross profit increased approximately 722% to $434,710

• Net loss down by approximately 38.3% to $82,613 or $0.00 per share

The Company posted the third consecutive quarter of triple digit revenue growth rates as compared to year earlier quarters.

“We had an excellent building quarter and we are pleased to have sustained our positive momentum for the year so far,” said Julian T. Ross, Chairman of the Board and Chief Executive Officer of OxySure. “Our results for the third quarter reflect our continued success at executing on strategic initiatives aimed at generating superior top-line growth while staying focused on controlling our expenses. We plan to continue our strategy of building awareness for our new and innovative lifesaving products, while investing in branding, distribution, R&D and sales. We are excited about some of the initiatives we are currently working on.”

For the three months ended September 30, 2013, revenues increased to $545,820, representing an increase of approximately $442,493 or 428% as compared to revenues of $103,327 for the three months ended September 30, 2012. For the nine months ended September 30, 2013, revenues increased to $1,262,311, representing an increase of approximately $1,068,209 or 550% as compared to revenues of $194,102 for the nine months ended September 30, 2012. The increase in revenues is primarily attributable to an increase in product sales in the United States, an increase in licensing/service revenues and an increase in sales of products developed for the military as part of a teaming agreement.

Gross profit was $434,710 for the three months ended September 30, 2013, an increase of $381,855 or 722% from $52,855 in the same period last year, primarily due to increased product sales, service revenues and license revenues.

Selling, general and administrative expenses were $478,518 compared to $206,810 for the comparable three months in 2012. The Company increased sales and marketing expenses from $7,234 to $77,841 as it expanded its sales and branding efforts. OxySure also recorded an increase in research and development expenses primarily attributable to an increase in research and development expense recognized in connection with products for military markets. Research and development expense during the three months ended September 30, 2013 was $134,357 as compared to $579 for the three months ended September 30, 2012. Other general and administrative expenses also increased by 34% to $266,320 as compared to $198,997 for the prior period. The increase in other general and administrative expense was primarily as a result of increases in depreciation and amortization expense, sales and marketing expense, research and development expense, and salaries and wages.

Interest expense fell 15% to $47,180 for the third quarter of 2013 from $55,461 during the third quarter of 2012.

Net loss decreased to $82,613, or $(0.00) per share, as compared to $133,779 or $(0.01) per share for the third quarter of 2012. The weighted average diluted shares outstanding were 24,076,789 and 20,761,595 for third quarters of 2013 and 2012, respectively.

Business updates

OxySure continues to execute on its core growth strategy of:

• Expand its sales and distribution footprint in the U.S. and internationally

• Leverage distribution partnerships to enhance market penetration

• Diversify product offerings through additions of complimentary or additive products/services

• Promote market awareness and education

• Pursue strategic alliances to further accelerate growth

Key milestones achieved so far in 2013 include:

1. Signed a distribution agreement with Dutch conglomerate Medizon B.V. to distribute products in the Netherlands, Belgium and Luxembourg

2. Signed a distribution agreement with Aero Healthcare to distribute products in Australia, New Zealand, and the United Kingdom

3. Launched a new product, a double wall cabinet to house a combination AED/OxySure system

4. Added new distributors in the United States to expand distribution footprint

5. Made significant progress towards the development of the military market in connection with a teaming agreement for the military

6. Made significant progress with regard to the CE Marking of the Company’s flagship product, the OxySure Model 615

7. Added Jerry M. Jones, former Chairman & CEO of Apria Healthcare to the Board of Directors

A link to a presentation of the company’s results can be found here: http://oxysure.com/3Q13_Earnings/OxySure_Earnings_Presentation_3Q13.pdf

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure’s products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other “Immediately Dangerous to Life or Health” (IDLH) environments. www.OxySure.com

Forward-Looking Statements

Statements in this earnings release that are not historical facts are considered to be forward-looking statements. Such statements include, but are not limited to, statements regarding management beliefs and expectations, based upon information available at the time the statements are made, regarding future plans, objectives and performance. All forward-looking statements are subject to risks and uncertainties, many of which are beyond management’s control and actual results and performance may differ significantly from those contained in forward-looking statements. OxySure Systems, Inc. intends any forward-looking statement to be covered by the Litigation Reform Act of 1995 and is including this statement for purposes of said safe harbor provisions. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. OxySure Systems, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances that occur after the date as of which such statements are made. A discussion of certain risks and uncertainties that could cause actual results to differ materially from those contained in forward-looking statements is included in OxySure Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2012.

Contacts:
Christian Hansen
Maximum Performance Advisors, Inc.
858-381-4677
christian@maximumperformanceadvisors.com

DreamTeamGroup (DTG)
Indianapolis, IN
www.DTG.fm
+1-317-623-3050 Direct
Editor@DTG.fm

MANCHESTER, NH–(Nov 14, 2013) – Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), an innovator developer of drugs that address diabetes using complex carbohydrate chemistry, will provide information about PAZ320, an investigational non-systemic chewable tablet, that when taken as an adjunctive therapy, helped patients with Type II diabetes manage the post meal elevation of their blood sugar in a Phase IIa clinical trial, at booth #127 at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia, November 13 to 15.

Edward Shea, Vice President of Business Development, Boston Therapeutics, Inc., commented, “Our participation in Obesity Week 2013 — the world’s largest event on obesity treatment and prevention — will further demonstrate Boston Therapeutics’ commitment to those patients suffering from obesity and one of its devastating complications: diabetes.”

About Obesity Week

Obesity Week 2013 is the inaugural event co-locating the American Society of Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS) annual meetings. In doing so, more than 60 years of combined experience in the study of obesity and its management are reflected in an interdisciplinary program from which all attendees will benefit. Both organizations have worked to give attendees the greatest value for their registration fee as they are able to attend both ASMBS and TOS Scientific Sessions. These sessions will include debates, key lectures, keynote speakers, networking/social events, oral presentations, panel discussions, paper and video sessions, poster presentations, partner and organizational symposiums. For more information, visit www.obesityweek.com.

About PAZ320

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company’s product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Vice President of Strategic Planning
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

CHARLOTTE, NC–(November 13, 2013) – Chanticleer Holdings, Inc. (NASDAQ: HOTR) (“Chanticleer Holdings” or “the Company”), headquartered in Charlotte, North Carolina, announced today that it closed a private offering, whereby the Company entered into a Subscription Agreement with three accredited investors, pursuant to which the Company sold to the Investors an aggregate of 160,000 Units at a purchase price of $5.00 per Unit, closing a $800,000 private placement. Each Unit consists of (a) 1 share of the Company’s common stock, $0.001 par value per share and (b) 1 5-year warrant to purchase 1 share of common stock. 80,000 warrants are available at an initial exercise price of $5.50, while the remaining 80,000 warrants are available at an initial exercise price of $7.00. Please see the accompanying Form 8-K filed for more details.

Mike Pruitt, the Company’s CEO stated, “Having access to capital at favorable rates allows us to continue to pursue opportunities as they present themselves.”

About Chanticleer Holdings, Inc.

Chanticleer Holdings (NASDAQ: HOTR) is focused on expanding the Hooters® casual dining restaurant brand in international emerging markets and American Roadside Burgers Inc (“ARB”), a Charlotte, N.C. based chain. Chanticleer currently owns in whole or part of the exclusive franchise rights to develop and operate Hooters restaurants in South Africa, Hungary and parts of Brazil, and has joint ventured with the current Hooters franchisee in Australia, while evaluating several additional international opportunities. The Company currently owns and operates in whole or part of six Hooters restaurants in its international franchise territories: Durban, Johannesburg, Cape Town and Emperor’s Palace in South Africa; Campbelltown in Australia; and Budapest in Hungary. ARB, purchased by Chanticleer Holdings on October 1, 2013, has a total of 5 casual restaurants — 1 location in Smithtown, N.Y., 2 locations in Charlotte, N.C., 1 location in Columbia, S.C., and the newest location is in Greenville, S.C. The Company also owns a majority interest in JF Restaurants, LLC and JF Franchising Systems, LLC, a fresh food-focused casual dining establishment with 5 restaurant locations.

For further information, please visit www.chanticleerholdings.com
Facebook: www.Facebook.com/ChanticleerHOTR
Twitter: http://Twitter.com/ChanticleerHOTR
Google+: https://plus.google.com/u/1/b/118048474114244335161/118048474114244335161/posts

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or required licenses, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contact:

Chanticleer Holdings, Inc.
Mike Pruitt
Chairman/CEO
Phone: 704.366.5122 x 1
mp@chanticleerholdings.com

MANCHESTER, NH–(Nov 13, 2013) – Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), an innovator of drugs that address diabetes using complex carbohydrate chemistry, reports its corporate update and financial results for the three and nine months ended September 30, 2013.

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “During the third quarter, we continued to build upon the positive results for PAZ320 obtained in our Phase IIa safety and efficacy trial. Specifically, with the initiation of our Phase IIb trial in France and the ongoing preparation for our planned Phase III multinational trial, we continue to develop what we believe will be a significant new tool as an adjunctive therapy in combination with metformin to treat Type 2 diabetes. I am especially excited about our new research study at the University of Minnesota, which we believe will give us deeper insights into how well PAZ320’s mechanism of action works non-systemically in the gastro-intestinal tract to block the uptake of glucose into the bloodstream.

“We also are enhancing our outreach programs at diabetes conferences, to the media to communicate the importance of our drug development initiatives to address a large unmet medical need, and to build awareness of who we are and what we do to the investment community. I am confident that we are on the right track and will continue to make progress in the months and years ahead,” he concluded.

Corporate Update:

• As of September 30, 2013, we had cash of approximately $3.9 million and current liabilities of approximately $340 thousand.
• Began enrollment for Phase IIb trial in France to assess the efficacy and safety of PAZ320 in patients with Type 2 diabetes as adjunctive therapy in combination with metformin.
• Began preparation for IND submission to the U.S. FDA for Phase III trial in the U.S., Europe, Hong Kong, and China to evaluate the effects of PAZ320 on post-meal glucose levels in patients with Type 2 diabetes as adjunctive therapy in combination with metformin.
• Initiated research study at the University of Minnesota to provide molecular-level data on PAZ320 and its mechanism of action, specifically to better characterize PAZ320 galactomannan and assess interactions of PAZ320 with various carbohydrate-hydrolyzing enzymes.
• Positive results from Phase II clinical trial was published by the principal investigator evaluating the safety and efficacy of PAZ320 (demonstrating significant 40% reduction in elevation of post-meal blood glucose) with no serious adverse events in patients in the July/August issue of peer-reviewed journal Endocrine Practice.
• Appointed Ed Shea, (25 years of bio-pharmaceutical experience in business development, sales and marketing, including 15 years with Glaxo Smithkline), as new Vice President of Business Development and Tina Gagnon (former Corporate Controller for Micronetics, Inc.) as new Director of Finance.
• Featured positive results from Phase II clinical trial at the 2013 American Association of Diabetes Educators Annual Meeting & Exhibition in Philadelphia.

Financial Results for the Third Quarter and Nine Months Ended September 30, 2013:

• Significantly strengthened the balance sheet with the closing of approximately $5.3 million in total gross proceeds from private placement of common stock and warrants to existing and new accredited investors. Use of proceeds is to primarily fund the Company’s ongoing clinical trials for PAZ320.
• Revenue for the third quarter was $217,520, compared with $2,520 in the prior year’s quarter. Nine-month revenue was $242,974, compared with $23,750 in the prior year’s nine-month period. The increase was primarily the result of shipments of the Company’s over-the-counter product to one customer.
• Gross margin for the three months ended September 30, 2013 was $99,005 as compared with a negative gross margin of ($6,600) for the three months ended September 30, 2012. Gross margin for the nine months ended September 30, 2013 was $68,550 as compared to negative gross margin of $(17,127). The increase is primarily related to the shipment of product during the third quarter. The negative gross margin for the three months and nine months ended September 30, 2012 was primarily the result of fixed overhead costs related to moving to a new fulfillment operation and manufacturing scale-up from small to production grade equipment exceeding revenue.
• Research and development expense for the three months ended September 30, 2013 was $151,946, an increase of $125,830 as compared to $26,116 for the three months ended September 30, 2012. Research and development expense for the nine months ended September 30, 2013 was $200,428, an increase of $54,760 as compared with $145,668 for the nine months ended September 30, 2012. The increase is primarily the result of increased activity for PAZ320’s Phase IIb trial in France and in preparation of PAZ320’s Phase III international trial.
• Sales and marketing expense for the three months ended September 30, 2013 was $102,840, an increase of $9,321 or 10% as compared with $93,519 for the three months ended September 30, 2012. Sales and marketing expense for the nine months ended September 30, 2013 was $251,236, an increase of $23,639 or 10% as compared with $227,597 for the nine months ended September 30, 2012. The expense consists primarily of costs incurred with third parties for product marketing and public relations.
• General and administrative expense for the three months ended September 30, 2013 was $954,261, an increase of $719,629 as compared with $234,632 for the three months ended September 30, 2012. Approximately $407,000 of the increase is related to non-cash stock-based compensation which includes $252,000 of expense due to the future vesting of stock options of a terminated employee and expense associated with stock option grants. Consulting and professional services increased $135,000 for investor relations and maintenance of the SUGARDOWN® website, accounting and legal professional fees increased $91,000 and payroll and payroll related expense increased $82,000 due to additional personnel.
• General and administrative expense for the nine months ended September 30, 2013 was $1,904,008, an increase of $1,405,405 as compared with $498,603 for the nine months ended September 30, 2012. Approximately $677,000 of the increase is related to non-cash stock-based compensation which includes $252,000 of expense due to future vesting of stock options of a terminated employee and expense associated with stock option grants during 2012 and 2013. Additionally, consulting and professional fees increased approximately $345,000 for investor relations and maintenance of the SUGARDOWN® website, payroll and related payroll expense increased $162,000 due to additional personnel, accounting and legal professional fees increased $114,000 due to increased business operations and rent expense increased $50,000 due to the new office facility.
• Net loss for the third quarter 2013 was $1,116,863 or $0.04 per share, compared with a net loss of $366,334, or $0.02 per share in the prior year’s third quarter. For the nine-month period, net loss was $2,303,532, or $0.11 per share, compared with $905,728 or $0.05 per share in 2012. Non-cash stock-based compensation of $472,820 and $857,851 is included in the net loss for the three months and nine months ended September 30, 2013.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH (OTCQB: BTHE), is an innovator in designing drugs using complex carbohydrate chemistry. The Company’s product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Vice President of Strategic Planning
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

NEW YORK, NY–(November 12, 2013) – JetBlue Airways (NASDAQ: JBLU) today announces its expanded winter schedule in the Caribbean, featuring more flights than ever before. With the planned launch of service to two new island destinations, JetBlue will serve the Caribbean region this winter with an average of 200 daily flights.

In addition to its own network growth, JetBlue also announces the signing of two new interline agreements in the Caribbean, with LIAT and Seaborne Airlines, and a growth of its existing partnership with Cape Air. This expands the single-ticket options for JetBlue customers into a number of additional Caribbean destinations.

Two new cities and five new routes planned

JetBlue has announced five new Caribbean routes that will launch in the coming months, including service to two new destinations: Port-au-Prince, Haiti and Port of Spain, Trinidad and Tobago (a). New routes include:

• Chicago (ORD) – San Juan, Puerto Rico (starts Nov. 20)
• Fort Lauderdale-Hollywood – Port-au-Prince, Haiti (starts Dec. 5) (a)
• Fort Lauderdale-Hollywood – Port of Spain, Trinidad and Tobago (starts May 1) (a)
• New York (JFK) – Port-au-Prince, Haiti (starts Dec. 5) (a)
• New York (JFK) – Port of Spain, Trinidad and Tobago (starts Feb. 24) (a)

Five destinations to see added capacity with larger aircraft

JetBlue plans to meet peak winter demand this winter by deploying its brand new Airbus A321 aircraft to a variety of Caribbean destinations. The A321 is outfitted with 190 seats, featuring the most legroom in coach (b), and boosting the number of seats per departure by 40 compared to JetBlue’s current 150-seat A320 aircraft. The following destinations will see select flights to/from New York (JFK) operated by the larger A321:

• Bridgetown, Barbados
• Nassau, Bahamas
• San Juan, Puerto Rico
• Santiago, Dominican Republic
• Santo Domingo, Dominican Republic

Additionally, JetBlue will offer even more frequencies between New York (JFK) and Barbados during peak holiday times, including President’s Day and Easter.

JetBlue’s A321s will be operating fresh from the factory and will not yet have in-flight television, radio or movies.

More destinations with new and expanded interline partnerships

JetBlue has added two new interline agreements, with LIAT and Seaborne Airlines, and expanded its existing partnership with Cape Air, bringing a number of new Caribbean destinations within reach for JetBlue customers.

LIAT now offers JetBlue customers connections to several new destinations including Antigua, Grenada, St. Kitts, and Saint Vincent and the Grenadines, when transferring at Barbados and St. Maarten. Founded in 1956, LIAT is one of the largest and most experienced carriers in the Caribbean region. Tickets are now available for sale through travel agencies.

Seaborne Airlines also opens up several new destinations for JetBlue customers, including St. Kitts, Dominica, and Guadeloupe and Martinique in the French Caribbean, all via San Juan, as well as connections to La Romana, Dominican Republic on a daily basis. In addition, Seaborne will offer more flight options for customers connecting at San Juan to/from both the U.S. and British Virgin Islands. Seaborne’s regional network includes 11 destinations from San Juan and a total of 625 weekly departures. JetBlue-Seaborne itineraries are now available for sale through travel agencies.

JetBlue’s longstanding partnership with Cape Air also expands this winter, with new destinations available via San Juan: Culebra, Puerto Rico, and Virgin Gorda in the British Virgin Islands. With service to these two unspoiled island destinations, which is expected to kick off in early 2014, Cape Air will serve a total of nine destinations from San Juan including options like Anguilla and Nevis. Tickets for travel to all Cape Air destinations in the Caribbean are available for sale at www.jetblue.com.

“It’s shaping up to be a great winter in the Caribbean region, with more JetBlue flights and more choices for travelers than ever before,” said Scott Laurence, JetBlue’s vice president of network planning. “Destination after destination, the Caribbean continues to embrace JetBlue’s unique brand of service. We’re excited to offer flights to 25 great getaways this winter plus even more destinations through our partnerships with Cape Air, LIAT, and Seaborne Airlines.”

About JetBlue in the Caribbean and Latin America

JetBlue is a leading airline in the Caribbean, soon offering nonstop service to 25 destinations across the region including Aguadilla; Aruba; Barbados; Bermuda; Cancún; Cartagena; Grand Cayman; Kingston; La Romana; Montego Bay; Nassau; Ponce; Port-au-Prince (a); Port of Spain (a); Providenciales; Puerto Plata; Punta Cana; Saint Lucia (Hewanorra); Samaná; San Juan; Santiago; Santo Domingo; St. Croix; St. Maarten; and St. Thomas. This winter JetBlue will operate an average of 200 flights to, from, and within the region.

The carrier operates one of its six focus cities at San Juan’s Luis Muñoz Marín International Airport, where it offers more flights to more destinations than any other carrier. In fact, this winter JetBlue will connect San Juan to 17 cities across the United States and Caribbean with an average of 40 daily departures. JetBlue is also a leading carrier in the Dominican Republic, serving more airports and offering more flights and more seats than any other U.S. carrier.

(a) Subject to receipt of government approval.

(b) Based on average fleet-wide seat pitch of U.S. airlines.

About JetBlue Airways
As New York’s Hometown Airline™ and a leading carrier in Boston, Fort Lauderdale-Hollywood, Los Angeles/Long Beach, Orlando and San Juan, JetBlue carries 30 million customers a year to 80 cities in the U.S., Caribbean and Latin America with an average of 750 daily flights. With JetBlue, all seats are assigned, all fares are one-way, and an overnight stay is never required. JetBlue’s fleet totals 191 aircraft, comprising 130 Airbus A320s, 1 A321 and 60 Embraer 190s. Upcoming destinations include Detroit, Mich. and Savannah, Ga.; as well as Port-au-Prince, Haiti; Port of Spain, Trinidad and Tobago; and Lima, Peru, subject to receipt of government approval. For more information please visit JetBlue.com.

MEDIA CONTACTS
JetBlue Corporate Communications
Tel: +1 718 709 3089
corpcomm@jetblue.com

MANCHESTER, NH–(Nov 12, 2013) – Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), an innovator in designing drugs that address diabetes using complex carbohydrate chemistry, today began enrolling patients in a Phase IIb clinical study on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of carbohydrate-hydrolyzing enzymes.

A total of 24 patients with Type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions. Patients’ blood glucose will be monitored using continuous glucose monitors (CGM) and their postprandial (after-meal) blood glucose levels will be measured following a test meal. The primary endpoint of the study is the evaluation of the effect of PAZ320 compared to placebo in the area under the curve (AUC) of glucose and on insulin levels in the blood for four hours following intake of the meal. The study is being conducted at Centre Hospitalier Robert Bisson, Lisieux, France.

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “This trial is designed to build upon the positive results from our Dartmouth Medical Center Phase IIa trial for PAZ320, recently published in the peer-reviewed journal, Endocrine Practice. In the Phase IIa study, PAZ320 was well tolerated in patients taking various anti-diabetic agents, including metformin. The Phase IIb trial, which focuses on patients taking only metformin, is the next step in the investigation of this compound as a potential adjunct to metformin in patients living with Type 2 diabetes. We believe it is important to better control glucose levels throughout the day, given the many complications that stem from uncontrolled diabetes.”

Metformin is the most widely prescribed drug for diabetes and often the first drug prescribed to newly diagnosed diabetes patients.

About PAZ320

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company’s product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Vice President of Strategic Planning
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com